Home

Insights

Shilpa Medicare Ltd dividend

Shilpa Medicare Ltd dividend

download
stocks purchased

₹ 0.7 Cr

Volume transacted

stocks purchased

13.8 K

stocks traded

Image

Shilpa Medicare Ltd

NSE: SHILPAMED

DPS

--

Last updated : FY 2023

Key Highlights

    The Dividend per Share of Shilpa Medicare Ltd is ₹ 0 as of 2023 .a1#The Dividend Payout of Shilpa Medicare Ltd changed from 6.57 % on March 2019 to 0 % on March 2023 . This represents a CAGR of -100.00% over 5 years. a1#The Latest Trading Price of Shilpa Medicare Ltd is ₹ 493 as of 27 May 15:30 .a1#The Market Cap of Shilpa Medicare Ltd changed from ₹ 2773 crore on March 2019 to ₹ 1990 crore on March 2023 . This represents a CAGR of -6.42% over 5 years. a1#The Revenue of Shilpa Medicare Ltd changed from ₹ 269.26 crore to ₹ 300.32 crore over 8 quarters. This represents a CAGR of 5.61% a1#The EBITDA of Shilpa Medicare Ltd changed from ₹ 27.94 crore to ₹ 78.54 crore over 8 quarters. This represents a CAGR of 67.66% a1#The Net Profit of Shilpa Medicare Ltd changed from ₹ 2.34 crore to ₹ 24.5 crore over 8 quarters. This represents a CAGR of 223.58% a1#

Open Demat Account

Lead form image

+91

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

*By signing up you agree to our terms & conditions

Share Price Vs Dividend Yield

swot
swot

Fundamental Metrics

Market Cap

5,106 Cr

EPS

0.0

P/E Ratio (TTM) *

0.0

P/B Ratio (TTM) *

2.2

DTE *

0.5

ROE *

-0.7

ROCE *

2.9

Dividend Yield *

0

DPS *

0

Dividend Payout *

0

Ann.Dividend % *

0

* All values are consolidated

* All values are consolidated

×

Dividend Payout Over Time

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Dividend Payout Over Time

Period
Mar '197
Mar '205
Mar '215
Mar '227
Mar '230

* All values are a in %

Dividend per Share (DPS) Over Time

×

DIVIDENDYIELD

Dividend Yield is a financial ratio that shows the annual dividend income relative to the market price of a share. It is calculated by dividing the dividend per share by the current market price per share, expressed as a percentage.

Dividend Yield Comparison With Top Peers

1M

1Y

3Y

5Y

* All values are in %

Net Profit Vs Dividend Per Share

Image

Shilpa Medicare Ltd

NSE: SHILPAMED

PRICE

493

-6.70(-1.34%)

stock direction

Last updated : 27 May 15:30

SWOT Analysis Of Shilpa Medicare Ltd

Strength

0

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

Dividend Overview for Shilpa Medicare Ltd

  • Shilpa Medicare Ltd, boasts of a market capitalization of Rs 5106 Cr., with a share price of Rs 493.00 as of 27 May 15:30. While all stocks don't consistently pay dividends, Shilpa Medicare Ltd rewarded its shareholders, distributing 0.0 % for the full year.
  • In the year ending 2022, Shilpa Medicare Ltd declared a dividend of Rs 1, resulting in a dividend yield of 0.3% Assessing its dividend-paying capacity and valuation is crucial to determine its suitability as a dividend stock.
  • During the year ending 2023, Shilpa Medicare Ltd recorded revenues of Rs 1123 Cr, with a trailing EBITDA Margin of 19.1% and net-profit of Rs -1 Cr

Overview of Dividend

Types of Dividend


Special Dividend

A dividend is paid on common stock when a company has accumulated substantial profits over years, often seen as excess cash that doesn't need immediate use.


Preferred Dividend

A quarterly dividend is paid to preferred stock owners, typically accumulating a fixed amount, and is earned on shares that function more like bonds.


Interim Dividend

Companies declare interim dividends before final full-year accounts are prepared, specifically in India, during the financial year from April to March of the following year.


Final Dividend

A final dividend is issued after the year's accounts have been compiled. Aside from this, the following list highlights the most prevalent sorts of dividends:


×

Market Cap Over Time

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Market Cap Over Time

Period
Mar '192774
Mar '201993
Mar '212721
Mar '223447
Mar '231991

* All values are a in crore

×

Revenue Over Time

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Revenue Over Time

Period
Jun '22269
Sep '22267
Dec '22266
Mar '22266
Jun '23262
Sep '23315
Dec '23289
Mar '23300

* All values are a in crore

×

EBITDA Over Time

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

EBITDA Over Time

Period
Jun '2228
Sep '2214
Dec '2234
Mar '2239
Jun '2348
Sep '2360
Dec '2367
Mar '2379

* All values are a in crore

×

Net Profit Over Time

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Net Profit Over Time

Period
Jun '222
Sep '22-19
Dec '22-7
Mar '22-8
Jun '231
Sep '232
Dec '235
Mar '2325

* All values are a in crore

About Shilpa Medicare Ltd

About Shilpa Medicare Ltd

    Shilpa Medicare Limited (formerly known as Shilpa Antibiotics Limited) was incorporated as a Private Limited Company in November 20th, 1987 and has been promoted by Vishnukant C Bhutada and his associates. Shilpa Medicare Limited (SML) is engaged in manufacturing of Active Pharmaceutical Ingredients (API), Formulation and Development service. The Company started its operations as API manufacturer way back in 1987 at Raichur, Karnataka. The company started commercial production in November 1989. In November 1993, Shilpa Medicare Limited was converted into a Public Limited Company. The Company is one of the leading API and formulations manufacturers with strong capabilities in the therapeutic area of oncology. It supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. While SML's underlying expertise is in the field of oncology, it also derives revenue from sale of non-oncology APIs. With key products being Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India. SML's product range includes over 44 oncology and non-oncology APIs. The Company's formulation product range consists of 16 injectable dosage forms, 19 oral solid dosage forms under SML and 13 formulations under SML's wholly owned subsidiary Shilpa Therapeutics Private Limited. SML deals in high-quality Active Pharmaceutical Ingredients (APIs), Bulk drug, Intermediates, Formulations and Development service, New Drug Delivery Systems, Peptides / Biotech products and Specialty Chemicals etc. using sophisticated technology meticulously in order to comply with laid down international standards/specifications. SML is among the world's leading suppliers of Oncology/Non-Oncology APIs and intermediates. In year 1992, the company installed production facilities to manufacture sodium methoxide. During FY 2015, projects of five products transfer executed successfully, other projects of eight products have been completed and ready for transfer to plant. Ten new molecules have been taken for development considering future demand. During FY15, as part of mobilization of resources for the purpose of expanding the operations of the Company, fresh funds were raised by allotting 17,64,705 equity shares of Rs.2/- each to Tano Mauritius India FVCI II, the existing member of the Company, at a premium of Rs 423/-each on 15 May 2014 on preferential basis. During FY2016, the company after obtaining the approval of members at the 28th Annual General Meeting held on 28 September, 2015, divided the face value of existing equity share of Rs.2/- into two equity shares of Re.1/- each fully paid-up, with effect from the Record Date specified. Raichem Medicare Pvt Ltd., a subsidiary of Shilpa Medicare, completed installation of all machineries during the FY 2015-2016 and recruited all the key personnel, also commenced trial production in August 2015 after the Audit by External Consultant from Italy and started commercial production in December-2015. The subsidiary obtained the Drug Manufacturing license and GMP certificate and consent from pollution control board for operating the plant. In FY 16-17, Shilpa Medicare launched the generic versions of Vidaza Injection & Xeloda Tablets. During the year under review, as part of mobilization of resources for the purpose of expanding the operations of the company, fresh funds were raised by allotting 30,25,000 equity shares of Re.1/- each to TA FII Investors Limited, at a premium of Rs.569/- each on 26 December, 2016 on preferential basis. Pursuant to the order dated 24 November 2017 of Hon'ble National Company Law Tribunal, Bangalore Bench, the Navya Biologicals Private Limited has been merged with the Company with effect from 1 April 2016 being the appointed date for merger. During the year 2019, an amount of Rs 22.71 crore was invested into its wholly owned subsidiary, Shilpa Therapeutics Pvt Ltd. (STPL) by way Loan to meet the project cost which is being set-up at Cherlapally, Telangana. During the year 2019, the Company disinvested 24% of stake in Raichem Medicare Private Limited, erstwhile Joint venture, and sold to Joint Venture Partner ICE S.p.A. In FY 2019, the company incorporated Shilpa Pharma Inc. as a wholly owned subsidiary in United States of America. During the current FY 2019-20, the Company formed Sravathi Advance Process Technologies Private Limited to foray into the R&D activities of specific drug processes by roping prominent technocrats. It launched the Indian branded generic of Ibrutinib, an anti-cancer drug under the brand name 'IBRUSHIL'. During the financial year 2019-2020, Shilpa launched Azacitidine, covering the majority of European countries. It launched the first Indian Branded Generic of Lenvatinib Mesylate under the brand name Lenshil which is used for the treatment of differentiated thyroid cancer (DTC) and hepatocellular carcinoma. It sold 26% stake and exited from in Raichem Medicare Private Limited, erstwhile Joint Venture, in the month of June, 2020. It incorporated Shilpa Albumin Private Limited and Shilpa Biologicals Private Limited as Wholly Owned Subsidiaries of the Company. In 2021, the Company launched a pediatric dose paracetamol oral thin film, under the brand name 'Molshil' in strengths of 60 mg and 120 mg. It commissioned the State of Art Centralized Finished Dosages R&D Centre at Dabaspet near Bangalore. In 2021, Shilpa Biologicals Pvt Ltd, (SBPL), a wholly owned subsidiary of Company signed an agreement with Dr. Reddy's Laboratories for production-supply of Sputnik V vaccine from its integrated Biologics R&D cum manufacturing center at Dharwad, Karnataka. It formed Sravathi AI Technology Private Limited, Shilpa Corporate Holdings Private Limited and Koanna Helathcare, Cananda. In FY22 the Company received an approval from the Defence Research & Development Organization (DRDO) for the manufacture and sale of 2-DeoxyD-Glucose (2DG). It commissioned a combo line for ODF/TDS. During the year 2021-22, Shilpa Corporate holdings Private Limited an investment company, has been formed as a wholly owned subsidiary, which acquired 100% stake in FTF Pharma Private Limited an an integrated drug development company, Koanaa Healthcare Canada, Koanaa International FZ LLC (Dubai), Indo Biotech SDN. BHD Malaysia, and so that all these companies have become as wholly Owned Subsidiaries. Further, the Company acquired balance 25% equity shares of INM Technologies Private Limited and made a wholly owned subsidiary. INM Technologies Private Limited which is the wholly owned subsidiary of the Company holds 25% of its stake in INM Nuvent Paints Private Limited. The Company had disposed off the total stake in Loba Feinchemie Gmbh, a step down subsidiary in Austria. In year 2022, the Company launched 12 formulations in India. The new launches were in the therapeutic areas of oncology, non-oncology, and products for the OTC market such as women hygiene, vitamin supplements and an antioxidant green tea film. It commissioned new R&D center for polymer & peptide, created separate wing for CDM0 with its scientific head. In 2022, the Shareholders of the Company have approved the Slump sale of Active Pharmaceutical Ingredient (API) Business of the Company consisting of Unit-1 and Unit-2 situated at Raichur, Karnataka to its wholly owned subsidiary Shilpa Pharma Lifesciences Limited. The Company, has duly executed the Business Transfer agreement with Shilpa Pharma Lifesciences Limited (Formerly known as Shilpa Corporate Holdings Private Limited) which is complete and effective from 30 June 2022.

Shilpa Medicare Ltd News Hub

News

Shilpa Medicare announces board meeting date

Shilpa Medicare will hold a meeting of the Board of Directors of the Company on 23 May 202...

Read more

16 May 2024 16:56

News

Shilpa Medicare announces launch of PEMRYDI RTU�

Shilpa Medicare's marketing partner, Amneal Pharmaceuticals, has launched PEMRYDI RTU� (Pe...

Read more

18 Apr 2024 09:54

News

Shilpa Medicare rises after marketing partner launches pemetrexed formulation in US

Pemetrexed injection is used as a drug, in the treatment of non-small cell lung cancer in ...

Read more

18 Apr 2024 09:44

News

Shilpa Medicare's Telangana facility gets Europe GMP Approval

The said unit of Shilpa Medicare is engaged in the manufacture, testing and distribution o...

Read more

17 Apr 2024 11:32

News

Shilpa Medicare allots 1.09 crore equity shares under QIP issue

Shilpa Medicare has allotted 1,09,89,010 equity shares of face value of Re 1 each to quali...

Read more

13 Apr 2024 11:19

News

Shilpa Medicare completes Rs 500-cr QIP issue of shares

The issue opened on Monday, 8 April 2024 and concluded on Friday, 12 April 2024, with a to...

Read more

13 Apr 2024 16:13

FAQs for dividends of Shilpa Medicare Ltd

What is the current market price of Shilpa Medicare Ltd Ltd as of May 27, 2024?

The current market price of Shilpa Medicare Ltd Ltd stands at 493.0 per share.

What dividend did Shilpa Medicare Ltd declare in the last fiscal year?

In the last fiscal year, Shilpa Medicare Ltd declared a dividend totaling ₹0.0.

What is the most recent dividend declared by Shilpa Medicare Ltd?

Shilpa Medicare Ltd recently declared a dividend of 0.0 in the latest quarter

How many times has Shilpa Medicare Ltd declared dividends in the current fiscal year

Shilpa Medicare Ltd has declared dividends 4 times totaling ₹0 in the current fiscal year (FY2023-2024).

How many times did Shilpa Medicare Ltd declare dividends in the previous fiscal year?

In the previous fiscal year (FY2022-2023), Shilpa Medicare Ltd declared dividends 4 times totaling ₹0.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199